Brett Wall is Executive Vice President and President of Medtronic’s Neuroscience Portfolio that is comprised of five unique Operating Units—Neuromodulation, Cranial & Spinal Technologies, Neurovascular, Pelvic Health and Ear, Nose and Throat. Together, these Operating Units generate over $8B in annual revenue and employ approximately 15,000 employees worldwide. Brett also serves as a member of the company’s Executive Committee.
Previously, he was Senior Vice President of the legacy Brain Therapies division which is part of the Neuroscience portfolio.
Brett also serves as the Executive Sponsor of the Medtronic African Descent Network — an internal national resource group that focuses on recruitment, engagement, retention and development for employees of African descent.
Prior to the Medtronic acquisition of Covidien, Brett served as Covidien President, Neurovascular and International, where he managed all commercial activities and functions of the business resulting in a doubling of revenue during his tenure.
He also served as Senior Vice President and President, Neurovascular; and Senior Vice President and President, International, at ev3, Inc. Prior to the ev3 merger with Micro Therapeutics, Brett held the positions of Micro Therapeutic Vice President, Marketing, for the Neurovascular and Peripheral Vascular divisions.
Brett’s career journey also included work at Boston Scientific as the Director of Marketing, Cardiovascular, Asia Pacific; and Marketing Manager, Japan, where he was responsible for the Interventional Cardiology product lines within the Asia-Pacific region. In addition, he held positions of increasing responsibility at C.R. Bard, where he was responsible for marketing the company’s suite of urological products.
Brett currently serves on the board executive committee for OCTANe, a group that promotes technical growth and expertise in the greater Orange County, California area. He also is a member of the CEO Roundtable at the University of California, Irvine. Previously, Brett served as Chairman of the Heart and Stroke Ball for the American Heart Association, Orange County Chapter.
Brett earned his bachelor’s degree in Comprehensive Business Administration with an emphasis in Marketing from the University of Nebraska at Kearney. He is a resident of Southern California.
What is Brett A. Wall's net worth?
The estimated net worth of Brett A. Wall is at least $2.63 million as of August 14th, 2023. Mr. Wall owns 33,573 shares of Medtronic stock worth more than $2,627,423 as of September 28th. This net worth estimate does not reflect any other investments that Mr. Wall may own. Learn More about Brett A. Wall's net worth.
How do I contact Brett A. Wall?
Has Brett A. Wall been buying or selling shares of Medtronic?
Within the last three months, Brett A. Wall has sold $259,320.00 of Medtronic stock. Most recently, Brett A. Wall sold 1,000 shares of the business's stock in a transaction on Monday, August 14th. The shares were sold at an average price of $83.38, for a transaction totalling $83,380.00. Following the completion of the sale, the executive vice president now directly owns 33,573 shares of the company's stock, valued at $2,799,316.74. Learn More on Brett A. Wall's trading history.
Who are Medtronic's active insiders?
Medtronic's insider roster includes Richard Anderson (Director), Michael Coyle (EVP), Gary Ellis (EVP), Hooman Hakami (EVP), Bryan Hanson (EVP), Omar Ishrak (Chairman), Richard Kuntz (SVP), Bradley Lerman (SVP), John Liddicoat (EVP), Michael Marinaro (EVP), Geoffrey Martha (CEO), Karen Parkhill (CFO), Sean Salmon (EVP), Gregory Smith (EVP), Carol Surface (SVP), Rob Ten Hoedt (EVP), Brett Wall (EVP), Brett Wall (EVP), and Robert White (EVP). Learn More on Medtronic's active insiders.
Are insiders buying or selling shares of Medtronic?
During the last year, insiders at the medical technology company sold shares 7 times. They sold a total of 38,901 shares worth more than $3,223,656.50. The most recent insider tranaction occured on August, 23rd when EVP Gregory L Smith sold 10,000 shares worth more than $838,400.00. Insiders at Medtronic own 0.3% of the company. Learn More about insider trades at Medtronic.
Information on this page was last updated on 8/23/2023.